Price Chart

Executive Summary

GT Biopharma entered into a securities purchase agreement to sell up to 41,778 shares of Series M 10% Convertible Preferred Stock and warrants for gross proceeds of up to $8,277,778 ($7,450,000 net after a 10% original issue discount). The offering includes a $30M greenshoe option and is highly dilutive, with a conversion/exercise price of $6.10 per share, subject to further price resets. The company also filed a Certificate of Designation for the preferred stock and a Registration Rights Agreement. This is a distressed financing by a micro-cap biotech with a $21M market cap, signaling acute capital needs and severe dilution risk for common shareholders.

Key Financial Metrics

Key Facts

• Company sold up to 41,778 shares of Series M 10% Convertible Preferred Stock for aggregate gross proceeds of up to $8,277,778 (net $7,450,000 after 10% OID).
• Investors receive common stock warrants for 100% of conversion shares, exercisable at $6.10 for 5 years.
• Greenshoe option allows investors to purchase up to an additional $33.3M stated value of preferred stock ($30M purchase price).
• Conversion price of $6.10 is subject to further downward adjustment via a price reset mechanism tied to Greenshoe exercises, with a floor of $1.282.
• Company must seek shareholder approval to issue shares exceeding 19.99% of outstanding common stock (Issuable Maximum of 360,695 shares).
• Lock-up agreements from directors, officers, and 10%+ stockholders are part of the transaction.
• Registration rights granted for resale of underlying shares; failure to register triggers 1.5% monthly liquidated damages.

Financial Impact

Up to $8.28M gross proceeds ($7.45M net) from the initial closing, with potential for up to $30M additional from greenshoe. Dilution is severe: at $6.10 conversion price, full conversion of initial preferred stock alone would add ~1.36M shares (assuming no floor), dwarfing the current ~3.4M share count implied by a $21M market cap at ~$6.17/share.

Risk Factors

• Extreme dilution to common shareholders from conversion of preferred stock and exercise of warrants.
• Conversion price reset mechanism (Greenshoe) could drive conversion price well below $6.10, increasing dilution.
• Company may fail to obtain shareholder approval for issuance above 19.99%, creating legal and operational risk.
• Micro-cap biotech with no disclosed revenue or pipeline progress; financing suggests cash burn is high and capital markets access is limited.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status